Page 1586 - Williams Hematology ( PDFDrive )

1560 Part XI: Malignant Lymphoid Diseases Chapter 93: Hairy Cell Leukemia 1561

70. Gidron A, Tallman MS: 2-CdA in the treatment of hairy cell leukemia: A review of 76. Maloisel F, Benboubker L, Gardembas M, et al: Long-term outcome with pentostatin
long-term follow-up. Leuk Lymphoma 47:2301–2307, 2006. treatment in hairy cell leukemia patients. A French retrospective study of 238 patients.
71. Jones G, Parry-Jones N, Wilkins B, et al: Revised guidelines for the diagnosis and Leukemia 17:45–51, 2003.
management of hairy cell leukaemia and hairy cell leukaemia variant. Br J Haematol 77. Burotto M, Stetler-Stevenson M, Arons E, et al: Bendamustine and rituximab in
156:186–195, 2012. relapsed and refractory hairy cell leukemia. Clin Cancer Res 19:6313–6321, 2013.
72. Flinn IW, Kopecky KJ, Foucar MK, et al: Long-term follow-up of remission duration, 78. Maurer H, Haas P, Wengenmayer T, et al: Successful vemurafenib salvage treatment in
mortality, and second malignancies in hairy cell leukemia patients treated with pen- a patient with primary refractory hairy cell leukemia and pulmonary aspergillosis. Ann
tostatin. Blood 96:2981–2986, 2000. Hematol 93:1439–1440, 2014.
73. Kreitman RJ, Tallman MS, Robak T, et al: Phase I trial of anti-CD22 recombinant 79. Cornet E, Delmer A, Feugier P, et al: Recommendations of the SFH (French Society of
immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy Haematology) for the diagnosis, treatment and follow-up of hairy cell leukaemia. Ann
cell leukemia. J Clin Oncol 30:1822–1828, 2012. Hematol 93:1977–1983, 2014.
74. Grever MR: Hairy cell: Young living longer but not cured. Blood 123:150–151, 2014.
75. Saven A, Burian C, Koziol JA, et al: Long-term follow-up of patients with hairy cell
leukemia after cladribine treatment. Blood 92:1918–1926, 1998.

Kaushansky_chapter 93_p1553-1562.indd 1561 9/18/15 3:47 PM